Arrowstreet Capital Limited Partnership Has $78.83 Million Stake in Solventum Co. (NYSE:SOLV)

Arrowstreet Capital Limited Partnership grew its holdings in shares of Solventum Co. (NYSE:SOLV - Free Report) by 41.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,193,361 shares of the company's stock after purchasing an additional 347,669 shares during the period. Arrowstreet Capital Limited Partnership owned 0.69% of Solventum worth $78,833,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of SOLV. Modus Advisors LLC bought a new stake in Solventum during the 4th quarter valued at $25,000. Stonebridge Financial Group LLC bought a new stake in shares of Solventum during the fourth quarter valued at about $26,000. Crews Bank & Trust acquired a new stake in Solventum in the fourth quarter worth about $32,000. True Wealth Design LLC increased its stake in Solventum by 23,550.0% during the 3rd quarter. True Wealth Design LLC now owns 473 shares of the company's stock valued at $33,000 after buying an additional 471 shares during the period. Finally, Synergy Asset Management LLC bought a new stake in shares of Solventum during the 4th quarter worth about $35,000.

Solventum Stock Up 0.3 %

NYSE SOLV traded up $0.20 during trading on Wednesday, reaching $76.54. 1,368,507 shares of the company's stock were exchanged, compared to its average volume of 1,392,568. The firm has a market capitalization of $13.24 billion and a PE ratio of 27.83. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $85.92. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The company's fifty day simple moving average is $75.66 and its 200-day simple moving average is $72.00.

Remove Ads

Analyst Ratings Changes

Several research firms have recently issued reports on SOLV. The Goldman Sachs Group increased their price objective on shares of Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a report on Monday, March 3rd. Bank of America lifted their price target on Solventum from $80.00 to $85.00 and gave the company a "neutral" rating in a research report on Wednesday, February 26th. Mizuho raised their target price on Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a research note on Monday, March 3rd. Piper Sandler boosted their price target on shares of Solventum from $75.00 to $84.00 and gave the stock a "neutral" rating in a research report on Friday, February 28th. Finally, Morgan Stanley raised their price objective on shares of Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a research report on Wednesday, March 5th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, Solventum presently has a consensus rating of "Hold" and a consensus price target of $79.86.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.